Defibrotide (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Defibrotide" in English language version.
Last modified:
Ref.Un. Ref.Website
Global rank
English rank
1st place
1st place
4,892nd place
3,451st place
4,353rd place
2,806th place
546th place
310th place
low place
6,199th place
low place
low place
canada.ca (Global: 1,114th place; English: 605th place)
- "Blood health (non-cancer)". Health Canada. 11 May 2018. Retrieved 13 April 2024.
cmocro.com (Global: low place; English: low place)
- "Marketing Approval of Defitelio by MHLW for the Treatment of Sinusoidal Obstruction Syndrome / Hepatic Veno-Occlusive Disease" (Press release). Nippon Shinyaku Co., Ltd. 18 June 2019. Retrieved 16 August 2020 – via CMOCRO.
doi.org (Global: 2nd place; English: 2nd place)
- Dalle JH, Giralt SA (March 2016). "Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment". Biology of Blood and Marrow Transplantation. 22 (3): 400–9. doi:10.1016/j.bbmt.2015.09.024. PMID 26431626.
europa.eu (Global: 62nd place; English: 100th place)
ema.europa.eu
- "Defitelio EPAR". European Medicines Agency (EMA). 21 April 2017. Retrieved 16 August 2020.
fda.gov (Global: 470th place; English: 329th place)
fda.gov
- "FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow". U.S. Food and Drug Administration (FDA) (Press release). March 30, 2016. Archived from the original on December 11, 2019.
This article incorporates text from this source, which is in the public domain.
accessdata.fda.gov
- "Defitelio Injection". U.S. Food and Drug Administration (FDA). 10 May 2016. Archived from the original on May 31, 2016. Retrieved 16 August 2020.
genengnews.com (Global: low place; English: 6,199th place)
- "Jazz Pharma Acquiring Gentium for $1B". GEN Genetic Engineering & Biotechnology News. December 20, 2013.
hres.ca (Global: low place; English: low place)
hpr-rps.hres.ca
- "Regulatory Decision Summary - Defitelio". Drug and Health Product Register. 23 October 2014. Retrieved 13 April 2024.
medicines.org.uk (Global: 4,892nd place; English: 3,451st place)
- "Defitelio 80 mg/mL concentrate for solution for infusion - Summary of Product Characteristics". UK Electronic Medicines Compendium. 26 May 2016. Retrieved 20 July 2017.
nih.gov (Global: 5th place; English: 5th place)
dailymed.nlm.nih.gov
- "Defitelio- defibrotide sodium injection, solution". DailyMed. 30 March 2016. Retrieved 16 August 2020.
pubmed.ncbi.nlm.nih.gov
- Dalle JH, Giralt SA (March 2016). "Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment". Biology of Blood and Marrow Transplantation. 22 (3): 400–9. doi:10.1016/j.bbmt.2015.09.024. PMID 26431626.
prnewswire.com (Global: 546th place; English: 310th place)
- "Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan" (Press release). Jazz Pharmaceuticals plc. 30 March 2017. Retrieved 16 August 2020 – via PR Newswire.
tga.gov.au (Global: 4,353rd place; English: 2,806th place)
- "Defitelio Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 31 July 2020. Retrieved 16 August 2020.
web.archive.org (Global: 1st place; English: 1st place)
- "FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow". U.S. Food and Drug Administration (FDA) (Press release). March 30, 2016. Archived from the original on December 11, 2019. This article incorporates text from this source, which is in the public domain.
- "Defitelio Injection". U.S. Food and Drug Administration (FDA). 10 May 2016. Archived from the original on May 31, 2016. Retrieved 16 August 2020.